Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don’t care about trying to save anybody & definitively don’t give a damn about any of those unwilling to accept / discuss $TSOI $Facts to date.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174693728
u have lost 10s of thousands
Nobody is saving anyone. These scumbags CEO Tim lil Dixon and Thomas POS Ichim want investors like myself who have lost 10s of thousands and some lost over 100k believing the lie upon lie upon lie. I for one am going nowhere. I will continue to post the facts about this share selling operation until it is shut down.
But hey the SEC "takes time" right.
They're saving us. I guess they don't know there's a lot of worse stocks in pinky land.
good question
With all this bad news on the company why do keep the stock .
***INVESTORS ALERT**** TSOI Corp, Thomas Ichim and Dr. James Veltmeyer are being sued for FRAUD, breach of Fiduciary Duty;
- Conversion;
-Accounting;
- Imposition of a Constructive
Trust; and
-Intentional Interference with
Contractual Relations
https://stocktwits.com/rustymaverick/message/568385484
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174129008&txt2find=
anyone feel SCAMMED here??? Thats because you were!!
A mission? please by al means enlighten me. I expose these scumbag criminals for what they are.
TSOI stock price did not not pump to .17 nor .13 on the basis of any actual accomplishments. It pumped on a mountain of deceit, lies and nothing burgers including:
-Positive StemVacs results and related talks of related INDS all of which went nowhere
-Master sales agreement that would purportedly gross 135 M
-Recurring/misleading claims that TSOI was a P3 bio company (we now know that the referenced trial was never ongoing and that the IND that TSOI attempted to purchase (but never did) did not seem to even include a master cell bank nor cells that were ready for registered clinical trials).
-Talk of partnerships that never went anywhere, let alone materialized
-Quadramune/Covid trials that petered out unsuccessfully
-Blood-Based Suicide Testing and Kaihani Score trials that also failed to finish
-Promised EUA filing which never occurred (promise broken)
-A bunch more BS
Eventually, TSOI's track record became clear as all of the "catalysts" that were marketed/hyped by TSOI supporters online for years failed, ceased, and/or were exposed. Logically, the stock price commenced a long and steady decline as it has lost nearly 100% of its value and is diluting out in the trips. Read it as slowly as needed!!!
Who knows how much the DOES own(ed) or when they have sold. What we know for sure is that the biggest sell off by far has been made by Dixon and Ichim, not the Does. As of 3.21, TSOI 2,223,741,391 OS. Now it has more than twice than that thanks to rampant and unsubsiding dilution.
Unsurprisingly, most investors (even Chat GPT 😂) have figured out TSOI's MO by now. Hence, the awful pps, the over whelming dilution and awful volume.
A mission? please by al means enlighten me. I expose these scumbag criminals for what they are.
Still believing all this BULLSHITE about phantom dividends. HAHAAHAHA....File a complaint with FINRA
https://www.finra.org/investors/need-help/file-a-complaint.
This is hilarious. Chat GPT is already a far more sophisticated investor than the typical TSOI bull. 🤣
The Mission is The Truth & The $Showing of $The $Corporate $Falsehoods Frankly speaking what are Falsehoods also called because
While we ALL wait & hope one day Dixon actually deliver on something other than the aforementioned that btw generates enough revenues so that shareholders NO longer are the funders of his Lifestyle & Dreams or even better spur interest of a real company to collaborate & potentially purchase.
Yet here you and several others, are still here. It just doesn't make sense to me. I know, ya'll on a crusade to protect us dumb investors. I have more respect for Johnnie, than the rest. He at least is on a mission.
After 13+ years $17M deficit so far w/ $2m deficit yearly & w/ NO generated revenue to cover operational cost over those years be called a bio company w/ NO Registered clinical trials
ChatGPT
A company in operation for over 13 years, with a $17 million accumulated deficit, $2 million yearly deficit, no generated revenue to cover operational costs, and no registered clinical trials, would have a difficult time being identified as a "biotech" or "bio" company by conventional standards. Here are some reasons why:
Key Characteristics of a Biotech Company
Research and Development (R&D): Biotech companies are heavily focused on R&D, developing new drugs, therapies, or biotech products.
Clinical Trials: A critical aspect of a biotech company's operations is conducting clinical trials to test the safety and efficacy of their products.
Regulatory Approvals: Successful biotech companies usually have a pipeline of products at various stages of development, often including regulatory approvals or pending approvals.
Scientific Innovation: Biotech companies are often founded on innovative scientific research and discoveries.
Analysis of the Given Company
No Clinical Trials: The lack of registered clinical trials suggests that the company may not be actively developing or testing new biotech products. Clinical trials are fundamental to the biotech industry, as they are necessary for bringing new therapies to market.
Financial Performance: The prolonged financial deficits without any generated revenue indicate significant challenges in advancing or commercializing any products or services.
Business Model and Operations: Without clinical trials or revenue, it is unclear what the company's business model and operational focus are. Biotech companies typically have a clear pipeline of products in various stages of development.
Conclusion
Based on the information provided, the company would not typically be recognized as a biotech or bio company because it lacks the essential elements that define such companies, especially clinical trials and R&D progress. Instead, the company may be perceived as one struggling to find its footing in its intended market or industry
Thanks Yoope, I thought it was too. That's why I stopped responding to it as if it was relevant to what I initially stated. 😜
Talk about deflection. Bio's take time, and lots of money to make it happen.
I don't remember a rush.
For the shareholder funded Lil Dix's Riding Mower https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174686462
Again, none of this has any bearing on the fact that suing the DOES, will not change the PPS. (Unless it's a blip)
The PPS is down, because the company cannot produce any real revenue stream and must rely on selling shares. (For a new gravel driveway to the retirement home.)
“The company started dumping shares into the pump, I was there, I saw it and knew to get out”
You knew to GET OUT? And this was almost 3 years ago? And when did YOU decide the dumping had ended and it was time to climb back aboard? What company event happened to bring you back into TSOI? Wasn’t there another 250,000,000 share dilution note already coming in January 2022? Or is this where you try to convince the board you currently are not a shareholder? Again, AFTER ALMOST 3 YEARS! Or are your daily posts here just a “distraction” since you got out in 2021?
The company started dumping shares into the pump, I was there, I saw it and knew to get out.
Now because all of this is just a distraction, as it is meant to be, I won't talk in circles with you any further. (I guess I forgot what communicating with you is like.) 🤪
Again, none of this has any bearing on the fact that suing the DOES, will not change the PPS. (Unless it's a blip)
The PPS is down, because the company cannot produce any real revenue stream and must rely on selling shares. (For a new gravel driveway to the retirement home.)
“But let's not forget who started the selloff”
Why don’t you tell the board who started the sell off? Was a 350% run from a proven unprofitable otc company supposed to hold its gains? Tell the board why the February 2021 run to .17 had a sell off first? Who started it? What could have been learned from the February 2021 sell off?
" ... should really examine their personal stock trading strategy! " We agree on that for sure. And some made much more than 350%, if they played the bounces on the way up and the way down.
But let's not forget who started the selloff. Maybe that is what turned some so negative.
Now, back to my original statement, since we all already know this subject so well.
" Namely, how badly the company has performed for it's shareholders. And suing the DOES won't fix that. "
https://www.barchart.com/stocks/quotes/TSOI/interactive-chart
T/A has Verified Timothy G Dixon, CEO is responsible for $TSOI’s Ongoing decrease in the pps.
Impact of dilution on earnings per share (EPS)
In the public markets, this can lead to a drop in stock price. For private companies, their profitability is often tied to valuation; as they move deeper down the transaction funnel, a reduced EPS can dissuade future investors and partners.
Is shareholder dilution bad?
Since the total value of the company is now divided among a greater number of shareholders, stock dilution can lower the value of existing shares. This can negatively impact the company's ability to raise additional capital, leading to a decline in investor confidence, and in turn may lower stock prices further.Aug 1, 2023
The company performed outstanding for its shareholders in 2021 as it went from sub penny levels to .17 then back down to .03 and up again to .13! Fortunes were made by many! Read it as slowly as needed! All stocks fluctuate in price as time goes by and anyone who didn’t notice how any of the 2021 gains didn’t hold almost immediately after reaching the top should really examine their personal stock trading strategy! Just look at the hundreds of false posts that started to exist shortly after the August 2021 sell off by the DOES that did nothing but brand TSOI in a false manner because this OTC PENNY STOCK SOLD OFF FROM ITS 350% RUN!!! It seems like as soon as the DOES otc investors investment went into the red, it’s not their fault and was considered unacceptable in such a short period of time! What comes after their investment shortly goes into red? The company is immediately labeled as a scam!!!
Im not even going to bother with these faux gift shares. They will end up being worthless.
Guess with the latest https://www.shutterstock.com/image-illustration/donkey-running-after-carrot-518056597 being release, we can expected the OS number to rise...once more.
I called schaub brokers they don't know anything tsoi made it very difficult. Now you got to print the paper work all over again . They are researching it got to call back Monday.
These dividend moves are certainly unorthodox. Don't forget to mention that the original dividend offer (for a higher ratio of CNSI stock) was withdrawn for "staleness" 🤣. How do you think everyone who rushed to buy in before the false dividend deadline back in 2023 only to see their investment lose ~80% in the months following feels about the dividend deadline and amount moving?
Chat GPT's take is very interesting. Thank you for sharing.
"If a company were to propose such a scheme involving an "elective dividend requiring personal info," it would likely face scrutiny from regulatory bodies, shareholders, and possibly legal challenges. Shareholders have rights to receive dividends in a fair and transparent manner, and any attempt to alter this process significantly would require careful legal consideration and approval."
Obviously time will tell. You have been saying that for years though and time has already told us a great deal about TSOI and it ain't good. Here you are on 4/23/21 saying you knew what was going to happen sooner or later. Did you know that TSOI would lose nearly 100% of its value since then? Did you see the dilution and ~2.5 billion additional shares being added? Did you sense that TSOI would never complete a single registered clinical trial in the more than 3 years that followed and have none current as of 7.1.24? Did you foresee all of the lies and unprofessionalism? Did your crystal ball indicate that TSOI and Ichim would be sued for fraud, breach of fiduciary duties and more? Per usual time did end up telling us all a great deal. Most reasonable investors would probably characterize the tale as a tragedy or a horror.
No argument with that statement Yoope.
Time will tell
Dixon/Doe(s) lawsuit obviously NOT going well Dixon still trying to get your personal info for a now so called "elective dividend" after transferring a previously owned shareholder asset; recommended ALL shareholders call your brokerage(s) & have them along w/ you Notify FINRA / SEC on your behalf & include the company provided link for said https://www.sec.gov/ix?doc=/Archives/edgar/data/0001419051/000149315224025700/form8-k.htm
-------------------------------------------------------------------------------------------
can publicly traded company divert their shareholder dividend issues for a transfer of previous shareholder asset by declaring only an elective dividend requiring your personal info instead of gong through the normal brokerage dividend process
ChatGPT
No, a publicly traded company cannot typically divert shareholder dividends in the manner described without adhering to legal and regulatory requirements. Here are some key points to consider:
Legal Obligations: Publicly traded companies are bound by securities laws and regulations that govern how dividends are declared and distributed. These laws ensure fairness and transparency in dividend payments to shareholders.
Dividend Declaration: Dividends are typically declared by the company's board of directors and distributed to shareholders through established processes. Shareholders expect to receive dividends through their brokerage accounts or directly from the company if they hold physical stock certificates.
Personal Information: Requiring personal information for an "elective dividend" in exchange for a transfer of previous shareholder assets raises red flags. Shareholders should not be compelled to provide personal information beyond what is necessary for regulatory or tax compliance purposes.
Brokerage Process: The normal brokerage dividend process involves crediting shareholders' accounts with the dividend amount based on their holdings. Any deviation from this process would need to be clearly communicated and compliant with regulatory requirements.
Transparency and Disclosure: Companies must disclose their dividend policies and any changes to shareholders. Any alternative dividend process would need to be transparent, well-documented, and approved in accordance with applicable laws.
If a company were to propose such a scheme involving an "elective dividend requiring personal info," it would likely face scrutiny from regulatory bodies, shareholders, and possibly legal challenges. Shareholders have rights to receive dividends in a fair and transparent manner, and any attempt to alter this process significantly would require careful legal consideration and approval.
You somehow turned my statement about this lawsuit not having any meaningful/lasting effect on the company PPS, into an argument about the legitimacy of the DOES case?
Maybe read it a little slower this time:
"Namely, how badly the company has performed for it's shareholders. And suing the DOES won't fix that."
They can file as many suits as they want, but it won't change how badly this company has performed for it's shareholders.
And now dividends? lol
A portion of nothing = Nothing
tsoi goes as promised
I'm a huge supporter of TSOI, but at this point with the dividend, why bother.
I'm annoyed that I did the paperwork needed last time, but it did not get executed. I have two Charles Schwab accounts (via td ameritrade) with TSOI and got no notification. For me trying to explain to Charles Schwab that they need to put their letter head on such and such document.... I don't see their customer service doing that.
Good luck to all who get the dividend, but I'll be getting nothing for my > 1 million shares in TSOI.
I'll just wait for success of the company itself....
Frankly speaking ownership of Lil Dix's riding mower
No, it’s not a class action! Congratulations on your 200 ma sell! Many sell their TSOI shares and keep coming back for more…
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173737142
Is that a class action? I’m down 15k thanks to these assholes. I know there are others aswell down more than me. How do I join
hahaahahahahahahahhahahahaahahahahh
Followers
|
528
|
Posters
|
|
Posts (Today)
|
28
|
Posts (Total)
|
64711
|
Created
|
10/04/08
|
Type
|
Free
|
Moderators BigBadWolf johnnytrader33 JMC$ Yooperman Hogwarts |
Preclinical Data Suggests QuadraMune™ Prevents Stress-Induced Suppression of Neurogenesis More Effectively than Prozac
OCEANSIDE, Calif., Dec. 9, 2020 /PRNewswire/ -- Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today new data suggesting the possibility that QuadraMune™ may mediate neuroprotective activity through preserving the ability of regenerative brain cells to proliferate subsequent to psychological stress.
The experiments, which involved exposing mice to established stressors, demonstrated that specific areas of the brain associated with production of new brain cells are damaged by stress. In agreement with previously published research, administration of fluoxetine (Prozac™) protected the brain from stress-induced damage. Surprisingly, QuadraMune™ administration appeared superior to Prozac™ at stimulating proliferation of new brain cells.
"QuadraMune™ which is currently in a clinical trial for prevention of COVD-191, has also been demonstrated to possess anti-inflammatory activity in other clinical trials, suppressing cytokines such as IL-62, which are known to be involved in depression3 and suicide4" said Kalina O'Connor, Director of Campbell Neurosciences and co-inventor on the patent. "Given major depressive disorder causes a significant risk for suicide, we are highly interested in exploring the use of QuadraMune™ for preventing suicide."
"Although much enthusiasm has been generated over the planned distribution of the COVID vaccine, at present little is being done to address mental health issues that are being exacerbated by the current pandemic" said Dr. James Veltmeyer, co-inventor of the patent, and Chief Medical Officer of the Company. "If current results are reproducible, the possibility that a nutraceutical would concurrently boost immunity while preserving mental health is highly enticing."
"It has not escaped us that COVID-19 is associated with increased inflammatory cytokines in the blood of patients, cytokines that also predispose to depression" said Famela Ramos, Vice President of Business Development for the Company. "It may be that the recent increase in suicides and suicide attempts is related biologically to activities of the coronavirus. It will be interesting to examine whether QuadraMune™ may modify putative negative mental effects of the virus."
"An estimated 17.3 million adults in the United States had at least one major depressive episode. This number represented 7.1% of all U.S. adults" stated Timothy Dixon, President and CEO of the Company. "We believe the Mission of our Company is not just providing a return on investment to our shareholders, but also increasing the quality of life for Americans. We are extremely pleased to report this unexpected finding with significant potential implications to advancing non-toxic means of helping patients with this terrible condition."
1 QuadraMune(TM) for Prevention of COVID-19 - Full Text View - ClinicalTrials.gov
2 Therapeutic Solutions International Announces Positive Preclinical and Clinical Evaluation of Nutritional Supplement QuadraMune™, Designed to Protect Against COVID-19 | BioSpace
3 Ting et al. Role of Interleukin-6 in Depressive Disorder. Int J Mol Sci. 2020 Mar 22;21(6):2194.
4 O'Donovan et al. Suicidal ideation is associated with elevated inflammation in patients with major depressive disorder. Depress Anxiety. 2013 Apr;30(4):307-14.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |